0001564590-20-037250.txt : 20200806 0001564590-20-037250.hdr.sgml : 20200806 20200806073032 ACCESSION NUMBER: 0001564590-20-037250 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 201079826 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 8-K 1 atrs-8k_20200806.htm 8-K ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION atrs-8k_20200806.htm
false 0001016169 0001016169 2020-08-06 2020-08-06

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2020

 

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

 

 

Delaware

 

1-32302

 

41-1350192

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

 

 

100 Princeton South, Suite 300, Ewing, NJ

 

08628

(Address of Principal Executive Offices)

 

(Zip Code)

(609) 359-3020

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

ATRS

 

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).  

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

 

Item 2.02

Results of Operations and Financial Condition.

On August 6, 2020, Antares Pharma, Inc. (the “Company”) issued a press release announcing its operating and financial results for the quarter ended June 30, 2020. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.

 

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

 

 

99.1

  

Press Release issued by Antares Pharma, Inc., dated August 6, 2020

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

ANTARES PHARMA, INC.

 

 

 

 

 

Date:

 

August 6, 2020

 

By:

 

/s/ Fred M. Powell

 

 

 

 

Name:

 

Fred M. Powell

 

 

 

 

Title:

 

Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 atrs-ex991_6.htm EX-99.1 PRESS RELEASE atrs-ex991_6.htm

EX 99.1

      

 

  

 

 

 

 

ANTARES PHARMA REPORTS STRONG SECOND QUARTER 2020 OPERATING AND FINANCIAL RESULTS; REINSTATES FULL-YEAR 2020 REVENUE GUIDANCE

 

 

•

Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019

 

 

•

Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019

 

 

•

Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million

 

 

EWING, NJ, August 6, 2020 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported operating and financial results for the second quarter ended June 30, 2020 with record second quarter revenue of $32.4 million and net income of $2.2 million, or earnings per share of $0.01. The Company also reported record six-month year-to-date revenue of $65.5 million, a 27% increase versus the first six months of 2019.

 

“I am very proud of the Antares team for delivering strong quarterly results while navigating the challenges presented by the COVID-19 pandemic. We remain committed to protecting the health and safety of our employees, patients, and health care providers while effectively operating our business to meet the needs of our partners and patients during this unprecedented time. The Company’s second quarter revenue of $32.4 million, which represents 14% year-over-year growth, was primarily driven by our proprietary product XYOSTED. The second quarter had the highest number of XYOSTED prescriptions to date, and we believe this is the result of the tremendous execution by our commercial team and highlights the demand for an easy to use, painless at-home testosterone injection option given limited physician and patient access at this time. Revenue from proprietary products, XYOSTED and OTREXUP, our highest margin products, grew 65% in the quarter versus the same period last year and now represent 60% of our total product revenue,” said Robert F. Apple, President and Chief Executive Officer of the Company.  

 

“We also continued to advance our product pipeline with the recently launched Teriparatide Injection (“teriparatide”) by Teva, the generic version of Eli Lilly’s brand Forsteo, in Canada and certain countries in Europe. According to Teva, the initial launch of teriparatide, which utilizes our multi-dose pen technology, will expand into other European countries later this year. Additionally, we look forward to a potential U.S. approval of a generic Forteo later this year. Finally, while the pandemic continues to pose some uncertainty for the second half of the year, we are encouraged by the growth of our business and the opportunities ahead, and therefore we have reinstated our revenue guidance for the full year,” Mr. Apple concluded.

 

Second Quarter 2020 and Recent Highlights

 

 

•

Reported second quarter total 2020 revenue of $32.4 million, an increase of 14% compared to the same period last year.  Proprietary product revenue increased 65% to $14.8 million as compared to $9.0 million in the second quarter of 2019.  Reported second quarter 2020 earnings per share of $0.01 as compared to a $0.01 loss per share reported in the comparable period last year.

 

 

 

 

 

•

According to Symphony Health Solutions, XYOSTED® total prescriptions increased 11% sequentially versus the first quarter of 2020.  Since the product launched, more than one hundred thirty-two thousand prescriptions of XYOSTED® have been written by almost six thousand different physicians.

 

 

•

Announced the first commercial product using Antares Pharma’s multi-dose pen platform was launched by the Company’s development partner Teva Pharmaceutical Industries, Ltd.  Teriparatide Injection, the generic version of Eli Lilly’s brand product Forsteo® was launched in Austria, Croatia, Denmark, Hungary, Ireland, The Netherlands, Portugal, Sweden, Switzerland, The United Kingdom as well as Canada and Israel.  Teva has indicated they expect to launch in other European countries later this year.

 

 

•

Announced an exclusive distribution agreement with Lunatus Global Medical Supplies to register, promote and distribute XYOSTED® in Saudi Arabia and the United Arab Emirates.

 

 

•

Cash, cash equivalents and short-term investments increased to $51.6 million at June 30, 2020, compared to $45.7 million at December 31, 2019.

 

 

Second Quarter 2020 Financial Results

 

Total revenue generated from product sales, development activities and royalties was $32.4 million for the three months ended June 30, 2020, a 14% increase compared to $28.4 million in the same period in 2019.  For the six months ended June 30, 2020, total revenue was $65.5 million, a 27% increase from $51.7 million for the comparable period in 2019.

Product sales were $24.7 million for the three months ended June 30, 2020, a 20% increase compared to $20.6 million for the same period in 2019.  For the six-month period ended June 30, 2020, product sales were $51.8 million, a 33% increase from $38.9 million in the comparable period in 2019.   

Sales of our proprietary products XYOSTED® and OTREXUP® generated revenue of $14.8 million and $27.4 million for the three and six months ended June 30, 2020, respectively, as compared to $9.0 million and $13.8 million for the three and six months ended June 30, 2019, respectively. The 65% and 99% increase in proprietary product sales for the three and six months ended June 30, 2020 respectively, compared to the three and six months ended June 30, 2019 were principally attributable to sales of XYOSTED®.  

Partnered device sales were $9.8 million and $11.6 million for the three months ended June 30, 2020 and 2019, respectively, and $24.4 million and $25.2 million for the six months ended June 30, 2020 and 2019, respectively. The decrease in sales of partnered products for the three and six months ended June 30, 2020 as compared to the same period in 2019 is primarily attributable to a decrease in sales of needle-free devices to Ferring, and a decrease in sales of Sumatriptan Injection USP and  teriparatide devices to Teva.  Antares previously announced the divestiture of the needle-free device to Ferring and shipment of pre-launch quantities of teriparatide devices to Teva during the first two quarters of 2019.

 

Licensing and development revenue was $2.7 million and $4.4 million for the three and six-month periods ended June 30, 2020, respectively, compared to $2.2 million and $3.2 million for the comparable periods in 2019, respectively. Licensing and development revenue for the three and six- month periods was primarily from the Pfizer rescue pen and the Idorsia selatogrel pen development programs.

 

Royalty revenue was $5.0 million for the three months ended June 30, 2020 compared to $5.6 million for the same period in 2019.  For the six-month period ended June 30, 2020, royalty revenue was $9.3 million, compared to $9.6 million for the same period in 2019.  The decrease in royalty revenue for the three and six-month periods were primarily attributable to a decline in royalties recognized from AMAG on their net sales of the Makena® subcutaneous auto injector.

 

 

 

 

Operating expenses were $16.9 million for the second quarter of 2020 compared to $17.6 million in the comparable period of 2019.  Total operating expenses for the six months ended June 30, 2020 were $36.3 million as compared to $34.9 million for the comparable period in 2019.  The increase in operating expenses for the six-month period of 2020 as compared to the same period in 2019 was primarily attributable to increased head count as well as increased non-cash incentive compensation expense.

 

Net income was $2.2 million, or $0.01 per share for the second quarter of 2020, compared to a net loss of $2.2 million, or $0.01 per share in the same period in 2019. Net loss was $0.2 million, or $0.00 per share for the six months ended June 30, 2020 compared to a net loss of $7.8 million, or $0.05 per share in the comparable period of 2019.  

 

At June 30, 2020, cash, cash equivalents and short-term investments were $51.6 million compared to $45.7 million at December 31, 2019.

 

2020 Financial Guidance

 

The Company today reinstated 2020 full-year revenue guidance in a range of $135 to $155 million, which represents a 9% to 25% year-over-year growth rate.  Given the unprecedented and unpredictable environment created by the COVID-19 pandemic, we reserve the right to revisit revenue guidance at some future point in time.

 

Webcast and Conference Call Information

 

Antares executives will provide a Company update and review second quarter 2020 financial results via webcast and conference call today, August 6, 2020, at 8:30 a.m. ET (Eastern Time). The webcast of the conference call, which will include a slide presentation, can be accessed through the link located on the “For Investors” section of the Company’s website (www.antarespharma.com) under “Webcasts & Presentations”.  Alternatively, callers may participate in the audio portion of the conference call by dialing toll free 1-800-353-6461, or 1-334-323-0501.  Callers should reference the Antares Pharma conference call or conference identification code 5888699. Callers can access the slide presentation on the “For Investors” section of the Company’s website under “Webcasts & Presentations”.  

 

A telephone replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, September 5, 2020. To access the replay, callers should dial 1-888-203-1112 or 1-719-457-0820 and enter passcode 5888699.  

 

About Antares Pharma

 

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma’s FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

 

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially

 

 

 

from those described.  Factors that may cause such differences include, but are not limited to: Teva’s successful commercialization of teriparatide injection in Europe and future revenue from the same; the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on reinstated 2020 full-year revenue guidance, demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; the ability of Lunatus to obtain regulatory approvals for XYOSTED® in Saudi Arabia and UAE and successfully commercialize the product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development;  actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

 

 

 

 

Contact:

Jack Howarth

Vice President, Corporate Affairs

609-359-3016

jhowarth@antarespharma.com

 

 

 

TABLES FOLLOW

 

 

 

 

 

ANTARES PHARMA, INC.

Table 1 - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(amounts in thousands except per share amounts)

(unaudited)

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

June 30,

 

 

Increase

 

 

June 30,

 

 

Increase

 

 

 

2020

 

 

2019

 

 

(Decrease)

 

 

2020

 

 

2019

 

 

(Decrease)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

24,665

 

 

$

20,620

 

 

20%

 

 

$

51,762

 

 

$

38,920

 

 

33%

 

Licensing and development revenue

 

 

2,687

 

 

 

2,239

 

 

20%

 

 

 

4,442

 

 

 

3,154

 

 

41%

 

Royalties

 

 

5,032

 

 

 

5,574

 

 

(10)%

 

 

 

9,259

 

 

 

9,645

 

 

(4)%

 

Total revenue

 

 

32,384

 

 

 

28,433

 

 

14%

 

 

 

65,463

 

 

 

51,719

 

 

27%

 

Cost of Revenue

 

 

12,477

 

 

 

12,441

 

 

0%

 

 

 

27,524

 

 

 

23,387

 

 

18%

 

Gross profit

 

 

19,907

 

 

 

15,992

 

 

24%

 

 

 

37,939

 

 

 

28,332

 

 

34%

 

Research and development

 

 

2,417

 

 

 

2,494

 

 

(3)%

 

 

 

5,398

 

 

 

4,881

 

 

11%

 

Selling, general and administrative

 

 

14,448

 

 

 

15,087

 

 

(4)%

 

 

 

30,870

 

 

 

30,022

 

 

3%

 

Total operating expenses

 

 

16,865

 

 

 

17,581

 

 

(4)%

 

 

 

36,268

 

 

 

34,903

 

 

4%

 

Operating income (loss)

 

 

3,042

 

 

 

(1,589

)

 

**

 

 

 

1,671

 

 

 

(6,571

)

 

**

 

Other expense

 

 

(867

)

 

 

(637

)

 

36%

 

 

 

(1,852

)

 

 

(1,194

)

 

55%

 

Net income (loss)

 

$

2,175

 

 

$

(2,226

)

 

**

 

 

$

(181

)

 

$

(7,765

)

 

(98)%

 

Net income (loss) per common share, basic and diluted

 

$

0.01

 

 

$

(0.01

)

 

 

 

 

 

$

(0.00

)

 

$

(0.05

)

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

165,703

 

 

 

162,734

 

 

 

 

 

 

 

165,566

 

 

 

161,596

 

 

 

 

 

Diluted

 

 

169,228

 

 

 

162,734

 

 

 

 

 

 

 

165,566

 

 

 

161,596

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANTARES PHARMA, INC.

Table 2 – CONSOLIDATED DETAIL OF REVENUE FROM PRODUCT SALES

(amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Product sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

XYOSTED®

 

$

10,902

 

 

$

4,623

 

 

$

19,905

 

 

$

5,326

 

OTREXUP®

 

 

3,944

 

 

 

4,361

 

 

 

7,507

 

 

 

8,429

 

Partnered product sales

 

 

9,819

 

 

 

11,636

 

 

 

24,350

 

 

 

25,165

 

Total product sales

 

$

24,665

 

 

$

20,620

 

 

$

51,762

 

 

$

38,920

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANTARES PHARMA, INC.

Table 3 – CONSOLIDATED CONDENSED BALANCE SHEETS

(amounts in thousands)

(unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Cash, cash equivalents and investments

 

$

51,550

 

 

$

45,721

 

Accounts receivable

 

 

34,293

 

 

 

35,074

 

Inventories

 

 

19,605

 

 

 

16,000

 

Contract assets

 

 

7,013

 

 

 

8,235

 

Equipment, molds, furniture and fixtures, net

 

 

19,452

 

 

 

15,961

 

Right of use assets

 

 

4,860

 

 

 

5,463

 

Other assets

 

 

6,351

 

 

 

6,297

 

Total Assets

 

$

143,124

 

 

$

132,751

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

37,633

 

 

$

30,677

 

Deferred revenue

 

 

2,341

 

 

 

1,738

 

Long-term debt and other liabilities

 

 

45,821

 

 

 

45,836

 

Stockholders’ equity

 

 

57,329

 

 

 

54,500

 

Total Liabilities and Stockholders’ Equity

 

$

143,124

 

 

$

132,751

 

 

 

 

 

 

 

 

 

 

 

 

 

 GRAPHIC 3 gbf3jx3kteou000001.jpg GRAPHIC begin 644 gbf3jx3kteou000001.jpg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atrs-20200806.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 atrs-20200806_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 atrs-20200806_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 atrs-8k_20200806_htm.xml IDEA: XBRL DOCUMENT 0001016169 2020-08-06 2020-08-06 false 0001016169 8-K 2020-08-06 ANTARES PHARMA, INC. DE 1-32302 41-1350192 100 Princeton South Suite 300 Ewing NJ 08628 (609) 359-3020 false false false false Common Stock, par value $0.01 per share ATRS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Aug. 06, 2020
Cover [Abstract]  
Entity Registrant Name ANTARES PHARMA, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001016169
Document Period End Date Aug. 06, 2020
Entity Emerging Growth Company false
Entity File Number 1-32302
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1350192
Entity Address, Address Line One 100 Princeton South
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Ewing
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08628
City Area Code (609)
Local Phone Number 359-3020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ATRS
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports atrs-8k_20200806.htm atrs-20200806.xsd atrs-20200806_lab.xml atrs-20200806_pre.xml atrs-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atrs-8k_20200806.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "atrs-8k_20200806.htm" ] }, "labelLink": { "local": [ "atrs-20200806_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "atrs-20200806_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "atrs-20200806.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atrs", "nsuri": "http://www.antarespharma.com/20200806", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20200806.htm", "contextRef": "C_0001016169_20200806_20200806", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20200806.htm", "contextRef": "C_0001016169_20200806_20200806", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.antarespharma.com/20200806/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-20-037250-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-037250-xbrl.zip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